CommercialCoverageMedium impact
08.01.73h, Filgrastim (Neupogen®) and Related Biosimilars, and tbo-filgrastim (Granix®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 1, 2025
We identified it
Jun 19, 2026
Summary
Commercial insurance policy for Filgrastim (Neupogen®) and related biosimilars, plus tbo-filgrastim (Granix®) has been updated. This affects billing for these white blood cell stimulating medications commonly used in oncology and hematology practices.
Action Required
By April 1, 2025: Billing team must review the full policy details at the provided URL to understand specific changes to Filgrastim and biosimilar coverage requirements. Update billing procedures accordingly for commercial plans. Contact oncology and hematology providers to ensure compliance with any new requirements.